Philippines: revenue of digestives & intestinal remedies

In the Philippines, digestives & intestinal remedies within the OTC pharmaceutical market generated approximately 60.3 million U.S. dollars in revenue in 2021. According to the Consumer Market Outlook, revenue in this segment will increase to roughly 63.6 million U.S. dollars by 2025.

Revenue of digestives & intestinal remedies in the Philippines from 2017 to 2025 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

The Digestives and Intestinal Remedies segment comprises over-the-counter natural and synthetic digestive agents and remedies against gastrointestinal complaints. Digestives include preparations in the form of pills, powder, capsules, liquids, solutions, suspensions, drops and suppositories. Not included are prescription medicines, preparations that are against the state law or are not explicit digestive drugs (e.g. painkillers). Among the top-selling digestives are Perenterol, Iberogast, Dulcolax and Buscopan Plus. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

All figures are estimates. Details on the methodology can be found at the Consumer Market Outlook.

Citation formats